These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

277 related articles for article (PubMed ID: 28520926)

  • 1. Investigation of miR-1202, miR-135a, and miR-16 in Major Depressive Disorder and Antidepressant Response.
    Fiori LM; Lopez JP; Richard-Devantoy S; Berlim M; Chachamovich E; Jollant F; Foster J; Rotzinger S; Kennedy SH; Turecki G
    Int J Neuropsychopharmacol; 2017 Aug; 20(8):619-623. PubMed ID: 28520926
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Co-Variation of Peripheral Levels of miR-1202 and Brain Activity and Connectivity During Antidepressant Treatment.
    Lopez JP; Pereira F; Richard-Devantoy S; Berlim M; Chachamovich E; Fiori LM; Niola P; Turecki G; Jollant F
    Neuropsychopharmacology; 2017 Sep; 42(10):2043-2051. PubMed ID: 28079059
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Alterations of microRNA-124 expression in peripheral blood mononuclear cells in pre- and post-treatment patients with major depressive disorder.
    He S; Liu X; Jiang K; Peng D; Hong W; Fang Y; Qian Y; Yu S; Li H
    J Psychiatr Res; 2016 Jul; 78():65-71. PubMed ID: 27078210
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Serum interleukin-6 is a predictive biomarker for ketamine's antidepressant effect in treatment-resistant patients with major depression.
    Yang JJ; Wang N; Yang C; Shi JY; Yu HY; Hashimoto K
    Biol Psychiatry; 2015 Feb; 77(3):e19-e20. PubMed ID: 25104172
    [No Abstract]   [Full Text] [Related]  

  • 5. Switching from Inadequate Adjunctive or Combination Treatment Options to Brexpiprazole Adjunctive to Antidepressant: An Open-Label Study on the Effects on Depressive Symptoms and Cognitive and Physical Functioning.
    Fava M; Okame T; Matsushima Y; Perry P; Weiller E; Baker RA
    Int J Neuropsychopharmacol; 2017 Jan; 20(1):22-30. PubMed ID: 27784751
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Plasma microRNA expression levels and their targeted pathways in patients with major depressive disorder who are responsive to duloxetine treatment.
    Kim HK; Tyryshkin K; Elmi N; Dharsee M; Evans KR; Good J; Javadi M; McCormack S; Vaccarino AL; Zhang X; Andreazza AC; Feilotter H
    J Psychiatr Res; 2019 Mar; 110():38-44. PubMed ID: 30580082
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Predicting Worsening Suicidal Ideation With Clinical Features and Peripheral Expression of Messenger RNA and MicroRNA During Antidepressant Treatment.
    Belzeaux R; Fiori LM; Lopez JP; Boucekine M; Boyer L; Blier P; Farzan F; Frey BN; Giacobbe P; Lam RW; Leri F; MacQueen GM; Milev R; Müller DJ; Parikh SV; Rotzinger S; Soares CN; Uher R; Foster JA; Kennedy SH; Turecki G
    J Clin Psychiatry; 2019 May; 80(3):. PubMed ID: 31087825
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Aberrant Expression of Intracellular let-7e, miR-146a, and miR-155 Correlates with Severity of Depression in Patients with Major Depressive Disorder and Is Ameliorated after Antidepressant Treatment.
    Hung YY; Wu MK; Tsai MC; Huang YL; Kang HY
    Cells; 2019 Jun; 8(7):. PubMed ID: 31252530
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Duloxetine plasma level and antidepressant response.
    De Donatis D; Florio V; Porcelli S; Saria A; Mercolini L; Serretti A; Conca A
    Prog Neuropsychopharmacol Biol Psychiatry; 2019 Jun; 92():127-132. PubMed ID: 30611837
    [TBL] [Abstract][Full Text] [Related]  

  • 10. BDNF plasma levels variations in major depressed patients receiving duloxetine.
    Fornaro M; Escelsior A; Rocchi G; Conio B; Magioncalda P; Marozzi V; Presta A; Sterlini B; Contini P; Amore M; Fornaro P; Martino M
    Neurol Sci; 2015 May; 36(5):729-34. PubMed ID: 25501804
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Using Epigenetic Tools to Investigate Antidepressant Response.
    Fiori LM; Lin R; Ju C; Belzeaux R; Turecki G
    Prog Mol Biol Transl Sci; 2018; 158():255-272. PubMed ID: 30072056
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The role of circulating blood microRNA-374 and microRNA-10 levels in the pathogenesis and therapeutic mechanisms of major depressive disorder.
    Liu W; Zhang F; Zheng Y; He S; Zhang T; Guo Q; Xu H; Chen H; Liu C; Yu S; Jiang K; Li H; Li G; Wang X; Liu X
    Neurosci Lett; 2021 Oct; 763():136184. PubMed ID: 34418506
    [TBL] [Abstract][Full Text] [Related]  

  • 13. What to expect from a third step in treatment resistant depression: A prospective open study on escitalopram.
    Souery D; Calati R; Papageorgiou K; Juven-Wetzler A; Gailledreau J; Modavi D; Sentissi O; Pitchot W; Papadimitriou GN; Dikeos D; Montgomery S; Kasper S; Zohar J; Serretti A; Mendlewicz J
    World J Biol Psychiatry; 2015 Oct; 16(7):472-82. PubMed ID: 25535987
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A pooled analysis of the efficacy of desvenlafaxine for the treatment of major depressive disorder in perimenopausal and postmenopausal women.
    Kornstein SG; Clayton AH; Bao W; Guico-Pabia CJ
    J Womens Health (Larchmt); 2015 Apr; 24(4):281-90. PubMed ID: 25860107
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Amygdala Reactivity to Emotional Faces in the Prediction of General and Medication-Specific Responses to Antidepressant Treatment in the Randomized iSPOT-D Trial.
    Williams LM; Korgaonkar MS; Song YC; Paton R; Eagles S; Goldstein-Piekarski A; Grieve SM; Harris AW; Usherwood T; Etkin A
    Neuropsychopharmacology; 2015 Sep; 40(10):2398-408. PubMed ID: 25824424
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Discovering biomarkers for antidepressant response: protocol from the Canadian biomarker integration network in depression (CAN-BIND) and clinical characteristics of the first patient cohort.
    Lam RW; Milev R; Rotzinger S; Andreazza AC; Blier P; Brenner C; Daskalakis ZJ; Dharsee M; Downar J; Evans KR; Farzan F; Foster JA; Frey BN; Geraci J; Giacobbe P; Feilotter HE; Hall GB; Harkness KL; Hassel S; Ismail Z; Leri F; Liotti M; MacQueen GM; McAndrews MP; Minuzzi L; Müller DJ; Parikh SV; Placenza FM; Quilty LC; Ravindran AV; Salomons TV; Soares CN; Strother SC; Turecki G; Vaccarino AL; Vila-Rodriguez F; Kennedy SH;
    BMC Psychiatry; 2016 Apr; 16():105. PubMed ID: 27084692
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of 50 and 100 mg desvenlafaxine versus placebo on sexual function in patients with major depressive disorder: a meta-analysis.
    Clayton AH; Hwang E; Kornstein SG; Tourian KA; Cheng RF; Abraham L; Mele L; Boucher M
    Int Clin Psychopharmacol; 2015 Nov; 30(6):307-15. PubMed ID: 26230270
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Two Phase III randomised double-blind studies of fixed-dose TC-5214 (dexmecamylamine) adjunct to ongoing antidepressant therapy in patients with major depressive disorder and an inadequate response to prior antidepressant therapy.
    Möller HJ; Demyttenaere K; Olausson B; Szamosi J; Wilson E; Hosford D; Dunbar G; Tummala R; Eriksson H
    World J Biol Psychiatry; 2015 Oct; 16(7):483-501. PubMed ID: 25602163
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Predictive socioeconomic and clinical profiles of antidepressant response and remission.
    Jain FA; Hunter AM; Brooks JO; Leuchter AF
    Depress Anxiety; 2013 Jul; 30(7):624-30. PubMed ID: 23288666
    [TBL] [Abstract][Full Text] [Related]  

  • 20. MiR-335 is involved in major depression disorder and antidepressant treatment through targeting GRM4.
    Li J; Meng H; Cao W; Qiu T
    Neurosci Lett; 2015 Oct; 606():167-72. PubMed ID: 26314506
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.